Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | USP2 | O75604 | 2/20 | 0.58 |
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.58 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.58 |
| ▸ | CA2 | P00918 | 3/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | SLC12A2 | P55011 | 1/20 | 0.54 |
| ▸ | CA12 | O43570 | 2/20 | 0.51 |
| ▸ | CA1 | P00915 | 2/20 | 0.51 |
| ▸ | CA9 | Q16790 | 2/20 | 0.51 |
| ▸ | TPMT | P51580 | 1/20 | 0.48 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11840209 | 0.91 | CA2 (0.50) | KDM4ELMNAALDH1A1USP2HPGD | |
| SCHEMBL11849986 | 0.90 | CA2 (0.49) | KDM4ELMNAALDH1A1USP2HPGD | |
| SCHEMBL15677242 | 0.90 | CA2 (0.49) | KDM4ELMNAALDH1A1USP2HPGD | |
| SCHEMBL11543992 | 0.89 | TPMT (0.54) | KDM4ELMNAALDH1A1USP2HPGD | |
| SCHEMBL572967 | 0.89 | LMNA (0.47) | KDM4ELMNAALDH1A1USP2HPGD | |
| SCHEMBL11547853 | 0.89 | LMNA (0.52) | KDM4ELMNAALDH1A1USP2HPGD | |
| SCHEMBL11547921 | 0.89 | ALDH1A1 (0.47) | KDM4ELMNAALDH1A1USP2HPGD | |
| SCHEMBL11849551 | 0.89 | ALDH1A1 (0.47) | KDM4ELMNAALDH1A1USP2HPGD | |
| SCHEMBL573787 | 0.88 | VCAM1 (0.53) | KDM4ELMNAALDH1A1USP2HPGD | |
| SCHEMBL11853767 | 0.88 | CA2 (0.48) | KDM4ELMNAALDH1A1USP2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117534594-A | Bumetanide intermediate and preparation method thereof | 宁波大红鹰药业股份有限公司 | 2024-02-09 | — | — | CN | claimed |
| CN-117567326-A | Preparation method of bumetanide | 山东诺明康药物研究院有限公司 | 2024-02-20 | — | — | CN | disclosed |
| CN-117534594-A | Bumetanide intermediate and preparation method thereof | 宁波大红鹰药业股份有限公司 | 2024-02-09 | — | — | CN | disclosed |
| CN-117534594-A | Bumetanide intermediate and preparation method thereof | 宁波大红鹰药业股份有限公司 | 2024-02-09 | — | — | CN | disclosed |
| US-20170246131-A1 | BUMETANIDE ANALOGS, COMPOSITIONS, AND METHODS OF USE | NEUROPRO THERAPEUTICS INC (US) | 2017-08-31 | — | — | US | disclosed |
| US-9682928-B2 | Bumetanide analogs, compositions and methods of use | NEUROPRO THERAPEUTICS, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| CN-105566175-A | Preparation method of 4-phenoxyl-5-aminosulfonyl-3-nitrobenzoic acid | NANJING ZHUOTAI PHARMACEUTICAL CO LTD | 2016-05-11 | — | — | CN | disclosed |
| CN-105566175-A | Preparation method of 4-phenoxyl-5-aminosulfonyl-3-nitrobenzoic acid | NANJING ZHUOTAI PHARMACEUTICAL CO LTD | 2016-05-11 | — | — | CN | disclosed |
| US-20150080350-A1 | BUMETANIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | NEUROPRO THERAPEUTICS INC. | 2015-03-19 | — | — | US | disclosed |
| US-20140128469-A1 | DEUTERATED N-BUTYL BUMETANIDE | CONCERT PHARMACEUTICALS INC. (US) | 2014-05-08 | — | — | US | disclosed |
| US-20080262086-A1 | SUBSTITUTED ANTHRANILIC ACIDS | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| US-4596791-A | Containing heterocyclic fused ring | USV PHARMACEUTICAL CORP. (US) | 1986-06-24 | — | — | US | disclosed |
| EP-0127124-A2 | Compounds for treating hypertension | USV PHARMACEUTICAL CORPORATION (US) | 1984-12-05 | — | — | EP | disclosed |
| EP-0121830-A2 | Substituted dipeptides as antihypertensives | USV PHARMACEUTICAL CORPORATION (US) | 1984-10-17 | — | — | EP | disclosed |
| US-4161531-A | Diuretic and saluretic 5-sulfamoylbenzoic acid derivatives carrying a heterocyclic substituent | HOECHST AKTIENGESELLSCHAFT (DE) | 1979-07-17 | — | — | US | disclosed |
| US-4118397-A | DIURETICS | HOECHST AKTIENGESELLSCHAFT (DE) | 1978-10-03 | — | — | US | disclosed |
| US-4111953-A | DIURETICS | HOECHST AKTIENGESELLSCHAFT (DE) | 1978-09-05 | — | — | US | disclosed |
| US-4093735-A | DIURETICS | HOECHST AKTIENGESELLSCHAFT (DT) | 1978-06-06 | — | — | US | disclosed |
| US-4010273-A | DIURETICS, SALURETICS | HOECHST AKTIENGESELLSCHAFT (DT) | 1977-03-01 | — | — | US | disclosed |
| US-3985777-A | Sulphamyl-benzoic acid derivatives | LOVENS KEMISKE FABRIK PRODUKTIONSAKTIESELSKAB (DK) | 1976-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262086-A1 | SUBSTITUTED ANTHRANILIC ACIDS | GLS, ASNS, REN | KDM4E 3887/4885LMNA 2117/4885ALDH1A1 1760/4885 |
| US-20140128469-A1 | DEUTERATED N-BUTYL BUMETANIDE | ABCB11, SLC10A1, CYP11B1 | KDM4E 1517/4885LMNA 3810/4885ALDH1A1 273/4885 |
| US-20170246131-A1 | BUMETANIDE ANALOGS, COMPOSITIONS, AND METHODS OF USE | SLC6A1, SLC6A13, SLC6A11 | KDM4E 2228/4885LMNA 3992/4885ALDH1A1 889/4885 |
| US-20150080350-A1 | BUMETANIDE ANALOGS, COMPOSITIONS AND METHODS OF USE | SLC6A1, SLC6A13, SLC6A11 | KDM4E 3717/4885LMNA 3842/4885ALDH1A1 845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.